Hemofarm plans new investments of EUR 100 million

Hemofarm is planning new investments in the amount of almost 100 million euros, and this year they expect double-digit growth, said Ronald Seeliger, CEO of Hemofarm.

Speaking about the planned investments, Seeliger pointed out that numerous projects are being prepared in the next few years, which will put Hemofarm ‘in the ranks of mega-production sites, even in the international framework’.

‘The amount of investment we are planning is close to 100 million euros and it will be invested in an area that will ensure a constant supply. This investment is part of our commitment and determination to secure the supply chain going forward’, Seeliger said and emphasized that in 2023 he expects double-digit growth.

‘It is always a little challenging to grow when you are the market leader, but still, we do like challenges. Year after year, we have been breaking our own business records, precisely as the result of continuous investments. Hemofarm is a modern organization with high standards comparable to any developed company in Germany or in the world. We are the proof that you can do business successfully in Serbia, of course under the conditions that apply to any business and anywhere in the world’, Seeliger said.

He reminded that this year Hemofarm introduced several new drugs on the market - for multiple sclerosis, which affects 10,000 people in Serbia, as well as a new flu antiviral product.

‘It’s important to take care of smaller patient groups, and we are proudly contributing to this. It is a part of our culture, our DNA, that is who we are’, said the CEO of Hemofarm Group.

Hemofarm operates in Serbia and the region as part of the STADA Group, which has a business tradition of more than a century and is one of the largest German investors in Serbia.

‘The best indicator of how important the Serbian market is for STADA Group is the investment of almost 450 million euros, which has been invested so far in Hemofarm. Serbia and the entire region of the Western Balkans are a very promising market for us, so we constantly strive to improve our business and strengthen our leadership position. We are on a quite exciting growth trajectory at this moment, and we are really committed to continue with this for the years to come. Our plan is to continue to invest intensively in the development of our employees and show by our example to others that changes for the better are always possible’, Ronald Seeliger said in the interview for ‘CORD’ magazine and reminded that a unique multimedia display STADA EXPO, was presented this year, which was created to offer the visitors an all-embracing experience about what sustainable development is and what it means when a pharmaceutical company cares about the future for all of us.